<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486434</url>
  </required_header>
  <id_info>
    <org_study_id>CSMC021C2301</org_study_id>
    <nct_id>NCT00486434</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Bioscience A/S</source>
  <brief_summary>
    <textblock>
      The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon
      calcitonin in the treatment of patients with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Joint Space Width (JSW) in the Medial Tibiofemoral Knee Joint in Signal Knee Measured by X-ray After 24 Months.</measure>
    <time_frame>Change from baseline to 24 months</time_frame>
    <description>The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscore in the Signal Knee</measure>
    <time_frame>Change from baseline to 24 months</time_frame>
    <description>WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Subscore in the Signal Knee.</measure>
    <time_frame>Change from baseline to 24 months</time_frame>
    <description>WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of difficulty for performing each daily function listed in the questionnaire. 0 is no difficulty (best), 100 is extreme difficulty (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 1700. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less difficulty).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Biochemical Markers of Bone &amp; Cartilage Metabolism.</measure>
    <time_frame>From Baseline to Month 24</time_frame>
    <description>The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX-I/creatinine and CTX-II/creatinine. It was originally planned that serum CTX-II would be measured, but this was not done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hand Osteoarthritis (OA) Assessed by X-ray &amp; Questionnaire From Baseline to 24 Months</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>To assess disease progression of OA affected joints, X-rays of both hands were performed &amp; assessed by two central readers (at Synarc). Hand OA was assessed by calculating total score for osteophytes, cyst erosion, &amp; joint space narrowing, each of which were based on sum of left and right hand X-ray analysis with possible scores of 0-66. The overall total score (possible range 0-198) was also used. Higher scores (closer to 66 or to 198 when using overall total score) imply a worse outcome. Hand analyses were based on double readings, and the mean was used in the analyses.
The AUStralian/CANadian Osteoarthritis Hand Index (AUSCAN) questionnaire was also used for assessment of hand OA. It measures pain (5 questions), stiffness (1 question) and difficulties with daily activities (9 questions) through a visual analogue scale (0-100mm; 0 = lowest score; 100 = highest score). Lower AUSCAN scores represent a better outcome. Change (from baseline to month 24) in these scores was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature and # of AEs Monitored Continuously During Study</measure>
    <time_frame>From Baseline to Month 24</time_frame>
    <description>Adverse events were by system organ class of all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Progression in the Knee Evaluated by MRI.</measure>
    <time_frame>From Baseline to Month 24</time_frame>
    <description>Disease progression in the signal knee (cartilage volume and thickness) were evaluated by magnetic resonance imaging (MRI). MRIs were performed for patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1176</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SMC021 Placebo, orally twice daily during 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMC021 Oral Calcitonin</intervention_name>
    <description>0.8mg SMC021 (Oral Calcitoinin) twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMC021 Placebo</intervention_name>
    <description>Placebo orally, twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medical history and symptoms of knee osteoarthritis

        Exclusion Criteria:

          -  Any other disease or medication affecting the bone or cartilage.

          -  Any clinical signs or laboratory evidence diseases, which in the Investigator's
             opinion would preclude the participant from adhering to the Protocol or completing the
             trial.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente J Riis, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Nordic Bioscience A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCBR Czech</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Aalborg</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Ballerup</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Vejle</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Estonia</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Osteoporozy i Chorób Kostno Stawowych, ul. Waryńskiego 6/2</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Poland</name>
      <address>
        <city>Warsaw</city>
        <zip>04703</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Romania</name>
      <address>
        <city>Bucharest</city>
        <zip>030463</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Hong Kong</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Lithuania</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <results_first_submitted>March 28, 2012</results_first_submitted>
  <results_first_submitted_qc>May 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2012</results_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, oral salmon calcitonin, treatment, efficacy, tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Arm</title>
          <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>1 SMC021 Placebo tablet twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="588"/>
                <participants group_id="P2" count="588"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="394"/>
                <participants group_id="P2" count="454"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Arm</title>
          <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>1 SMC021 Placebo tablet twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="588"/>
            <count group_id="B2" value="588"/>
            <count group_id="B3" value="1176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="321"/>
                    <measurement group_id="B3" value="614"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="6.84"/>
                    <measurement group_id="B2" value="63.9" spread="6.41"/>
                    <measurement group_id="B3" value="64.0" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="418"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="804"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Joint Space Width (JSW) in the Medial Tibiofemoral Knee Joint in Signal Knee Measured by X-ray After 24 Months.</title>
        <description>The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.</description>
        <time_frame>Change from baseline to 24 months</time_frame>
        <population>The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Joint Space Width (JSW) in the Medial Tibiofemoral Knee Joint in Signal Knee Measured by X-ray After 24 Months.</title>
          <description>The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.</description>
          <population>The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.188" spread="0.5626"/>
                    <measurement group_id="O2" value="-0.198" spread="0.5069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscore in the Signal Knee</title>
        <description>WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).</description>
        <time_frame>Change from baseline to 24 months</time_frame>
        <population>The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Subscore in the Signal Knee</title>
          <description>WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).</description>
          <population>The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-124.0" lower_limit="-391" upper_limit="218"/>
                    <measurement group_id="O2" value="-109.0" lower_limit="-410" upper_limit="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Subscore in the Signal Knee.</title>
        <description>WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of difficulty for performing each daily function listed in the questionnaire. 0 is no difficulty (best), 100 is extreme difficulty (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 1700. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less difficulty).</description>
        <time_frame>Change from baseline to 24 months</time_frame>
        <population>The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function Subscore in the Signal Knee.</title>
          <description>WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of difficulty for performing each daily function listed in the questionnaire. 0 is no difficulty (best), 100 is extreme difficulty (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 1700. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less difficulty).</description>
          <population>The number of participants analysed for this outcome is the intent-to-treat (ITT) population. ITT is the number of randomized subjects who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the ITT analysis.</population>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-390.0" lower_limit="-1307" upper_limit="783"/>
                    <measurement group_id="O2" value="-299.5" lower_limit="-1342" upper_limit="915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biochemical Markers of Bone &amp; Cartilage Metabolism.</title>
        <description>The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX-I/creatinine and CTX-II/creatinine. It was originally planned that serum CTX-II would be measured, but this was not done.</description>
        <time_frame>From Baseline to Month 24</time_frame>
        <population>ITT Population. The number analyzed in some rows differs from the overall number analyzed due to missing values from patients who prematurely discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biochemical Markers of Bone &amp; Cartilage Metabolism.</title>
          <description>The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX-I/creatinine and CTX-II/creatinine. It was originally planned that serum CTX-II would be measured, but this was not done.</description>
          <population>ITT Population. The number analyzed in some rows differs from the overall number analyzed due to missing values from patients who prematurely discontinued.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum CTX-I (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.358" spread="68.1153"/>
                    <measurement group_id="O2" value="62.883" spread="65.7225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Osteocalcin (ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="578"/>
                    <count group_id="O2" value="577"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.134" spread="22.1368"/>
                    <measurement group_id="O2" value="1.785" spread="22.8324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-h urine CTX-I/creatinine (µg/mmol)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="574"/>
                    <count group_id="O2" value="571"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.959" spread="50.0723"/>
                    <measurement group_id="O2" value="8.311" spread="55.4934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-h urine CTX-II/creatinine (ng/mmol)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="574"/>
                    <count group_id="O2" value="571"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.484" spread="56.4879"/>
                    <measurement group_id="O2" value="11.266" spread="49.6250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hand Osteoarthritis (OA) Assessed by X-ray &amp; Questionnaire From Baseline to 24 Months</title>
        <description>To assess disease progression of OA affected joints, X-rays of both hands were performed &amp; assessed by two central readers (at Synarc). Hand OA was assessed by calculating total score for osteophytes, cyst erosion, &amp; joint space narrowing, each of which were based on sum of left and right hand X-ray analysis with possible scores of 0-66. The overall total score (possible range 0-198) was also used. Higher scores (closer to 66 or to 198 when using overall total score) imply a worse outcome. Hand analyses were based on double readings, and the mean was used in the analyses.
The AUStralian/CANadian Osteoarthritis Hand Index (AUSCAN) questionnaire was also used for assessment of hand OA. It measures pain (5 questions), stiffness (1 question) and difficulties with daily activities (9 questions) through a visual analogue scale (0-100mm; 0 = lowest score; 100 = highest score). Lower AUSCAN scores represent a better outcome. Change (from baseline to month 24) in these scores was calculated.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>About 15% of the ITT population had hand OA at baseline and only these subjects were included in the X-ray assessments.The AUSCAN questionnaire was administered to all the patients at sites in Denmark, the Czech Republic, and Romania.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hand Osteoarthritis (OA) Assessed by X-ray &amp; Questionnaire From Baseline to 24 Months</title>
          <description>To assess disease progression of OA affected joints, X-rays of both hands were performed &amp; assessed by two central readers (at Synarc). Hand OA was assessed by calculating total score for osteophytes, cyst erosion, &amp; joint space narrowing, each of which were based on sum of left and right hand X-ray analysis with possible scores of 0-66. The overall total score (possible range 0-198) was also used. Higher scores (closer to 66 or to 198 when using overall total score) imply a worse outcome. Hand analyses were based on double readings, and the mean was used in the analyses.
The AUStralian/CANadian Osteoarthritis Hand Index (AUSCAN) questionnaire was also used for assessment of hand OA. It measures pain (5 questions), stiffness (1 question) and difficulties with daily activities (9 questions) through a visual analogue scale (0-100mm; 0 = lowest score; 100 = highest score). Lower AUSCAN scores represent a better outcome. Change (from baseline to month 24) in these scores was calculated.</description>
          <population>About 15% of the ITT population had hand OA at baseline and only these subjects were included in the X-ray assessments.The AUSCAN questionnaire was administered to all the patients at sites in Denmark, the Czech Republic, and Romania.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total osteophytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.784"/>
                    <measurement group_id="O2" value="0.40" spread="0.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total JSN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="1.063"/>
                    <measurement group_id="O2" value="0.62" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cyst/erosions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.204"/>
                    <measurement group_id="O2" value="0.82" spread="1.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total osteophytes, JSN and cyst/erosions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="2.682"/>
                    <measurement group_id="O2" value="1.84" spread="2.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUSCAN total score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="297"/>
                    <count group_id="O2" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.5" spread="265.13"/>
                    <measurement group_id="O2" value="-38.1" spread="272.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nature and # of AEs Monitored Continuously During Study</title>
        <description>Adverse events were by system organ class of all patients.</description>
        <time_frame>From Baseline to Month 24</time_frame>
        <population>ITT population. A patient with multiple occurrences of a TEAE under one treatment is counted only once in the AE category for that treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total number of subjects between the two groups</description>
          </group>
        </group_list>
        <measure>
          <title>Nature and # of AEs Monitored Continuously During Study</title>
          <description>Adverse events were by system organ class of all patients.</description>
          <population>ITT population. A patient with multiple occurrences of a TEAE under one treatment is counted only once in the AE category for that treatment.</population>
          <units>Number of AEs by system organ class</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
                <count group_id="O3" value="1169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any primary system organ class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="548"/>
                    <measurement group_id="O2" value="520"/>
                    <measurement group_id="O3" value="1068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital, familial and genetic disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and labyrinth disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="150"/>
                    <measurement group_id="O3" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders and administration site condit.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="249"/>
                    <measurement group_id="O3" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning and procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="267"/>
                    <measurement group_id="O3" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms benign, malignant and unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive system and breast disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical and medical procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression in the Knee Evaluated by MRI.</title>
        <description>Disease progression in the signal knee (cartilage volume and thickness) were evaluated by magnetic resonance imaging (MRI). MRIs were performed for patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.</description>
        <time_frame>From Baseline to Month 24</time_frame>
        <population>MRIs were performed for patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>1 SMC021 Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression in the Knee Evaluated by MRI.</title>
          <description>Disease progression in the signal knee (cartilage volume and thickness) were evaluated by magnetic resonance imaging (MRI). MRIs were performed for patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.</description>
          <population>MRIs were performed for patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cartilage volume m12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="10.104"/>
                    <measurement group_id="O2" value="0.26" spread="9.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cartilage volume m24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="10.352"/>
                    <measurement group_id="O2" value="1.94" spread="9.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cartilage thickness m12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9921" spread="7.05068"/>
                    <measurement group_id="O2" value="0.4343" spread="6.90177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cartilage thickness m24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1777" spread="6.22356"/>
                    <measurement group_id="O2" value="2.2467" spread="7.09590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline until 30 days following the end of study.</time_frame>
      <desc>The safety population is all patients randomized who received at least one dose of study medication. There were 7 patients in the randomized population who did not receive any study drug and where therefore excluded from the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Arm</title>
          <description>0.8mg SMC021 Oral Calcitonin tablet twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>1 SMC021 Placebo tablet twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Coronary artery dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Uterine leimyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urethral prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary retension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Peau d´orange</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bone graft</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abscess drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cardial pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Radical hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="548" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="520" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Viral infections</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bente Juel Riis, Medical Director</name_or_title>
      <organization>Nordic Bioscience A/S</organization>
      <phone>+4522901317</phone>
      <email>bjr@nordicbioscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

